Cyrona Cell uses Wharton’s Jelly mesenchymal cells that have been derived from infant umbilical cords as they can:

As Parkinson’s disease is a neurodegenerative disorder that is caused by the death of specific neurons and axons that produce the organic chemicals responsible for movement, the aim of cell therapy is to prevent further deterioration, decrease neuronal death, decrease involuntary movements (rotations), improve motor skills and coordination, and increase the production of neurons.
Scientifically-Proven Results
|
University/Centre |
Results |
|
|
2009 |
National Yang-Ming University, Taiwan |
Decreased the number of rotations. |
|
2009 |
Kansas State University, United States |
Significantly improved the clinical symptoms, increased number of specialised neuron-like cells at the injury site, and decreased the number of rotations. |
|
2011 |
Huazhong University of Science and Technology, China |
Able to decrease the loss of specialised neuron-like cells and increase its production in vivo (in the body) as well as decreased the number of rotations. |
|
2013 |
College of Veterinary Medicine, Korea |
Improved motor behaviour. |
|
2013 |
Yunnan Engineering Research Center of Vaccine Research and Development on Severe Infectious Diseases, China |
Increased vigorous movements, balance ability, and motor movements, decreased the number of rotations, and decrease the loss of specialised neuron-like cells and increase its production in vivo (in the body). |
|
2013 |
Reliance Life Sciences Pvt Ltd, India |
Decreased the number of rotations by 80% in 4 to 6 months as well as improved motor coordination. |
|
2016 |
Shahid Beheshti University of Medical Sciences and the National Institute of Genetic Engineering and Biotechnology, Iran |
Decreased neuronal death and decreased the number of rotations. |
Achieving high standards in our work is of paramount importance to us. As such, we only produce and use premium grade passage 1 (P1) and passage 2 (P2) Wharton’s Jelly mesenchymal stem cells in all our therapy programmes. These cellular products have also been thoroughly screened and analysed in accordance with the requirements of The International Society for Cellular Therapy prior to use.
We also use the latest in cellular research and technologies to tailor our therapy programmes according to the needs of the individual. Furthermore, our microbiology and clinical team as well as our extensively experienced board-certified physicians are geared towards your safety and wellbeing.
All our therapy programmes are conducted using premium grade P1 and P2 Wharton’s Jelly mesenchymal cells and by board-certified experienced specialists. All patients are also provided with pre-transfusion analysis reports of any and all cellular and supplementary products used during treatment.
International patients will be provided with airport transfer services and accommodations as well as in-city transportation to and from every therapy session.
As no two people are alike, our specialists review each patient’s medical reports before developing the best treatment protocol to addresses their unique needs. Therefore, before speaking to one of our Customer Service Representatives, it is best to have the following handy:
Download our eBook and receive our weekly in-depth and exclusive newsletter about Parkinson's Disease.